Prenatal Care & Testing
Understanding NIPT Results: False Positives and What PPV Means
A positive NIPT is a probability, not a diagnosis. Here is what positive predictive value actually means for Down syndrome, trisomy 13, and sex chromosome results — and why confirmatory testing matters before any decision.
Clinically reviewed · June 2026
A positive NIPT result is not a diagnosis — it is a probability estimate. How meaningful that probability is depends on which condition was flagged, your age, and other risk factors. For trisomy 21 in an average population, roughly 86 out of 100 positive results are true positives; for trisomy 13 or Turner syndrome, most positive results are false positives. Confirmatory invasive testing is always the next step before any clinical decision is made.
When a non-invasive prenatal test (NIPT) comes back with a high-risk result, the first thing most parents hear is a number: "positive for trisomy 21" or "high risk for Turner syndrome." What they often don't hear — and what matters enormously for what happens next — is that a positive NIPT is a screening flag, not a confirmed diagnosis. Understanding a concept called positive predictive value is the clearest way to make sense of what that flag really means.
This article is general educational information, not medical advice. If you have received a positive NIPT result, please discuss next steps with your OB-GYN, midwife, or maternal-fetal medicine specialist before making any decisions.
What Is Positive Predictive Value (PPV) — and Why Does It Vary So Much?
Positive predictive value is the probability that a positive test result corresponds to a real finding. For NIPT, it answers the question: "If my result says high-risk for this condition, what are the chances my baby actually has it?"
Here is what makes PPV different from the accuracy statistics labs advertise. Tests are typically marketed by their sensitivity (how well they catch true cases) and specificity (how rarely they flag false ones). NIPT performs excellently on both metrics: sensitivity exceeds 99% for trisomy 21, and false-positive rates are below 0.1% to 0.2% for the common trisomies. Those numbers sound reassuring — until you factor in how rare these conditions actually are in the screened population.
Rarer conditions produce fewer true positives in any group. So even a very specific test will generate a disproportionately large share of false positives when the condition it is detecting is uncommon. That mathematical reality is captured in PPV — and it explains why a positive result for a relatively common condition like Down syndrome carries much more weight than a positive result for a rarer one like trisomy 13.
A systematic analysis of 468 NIPT-positive cases from a real prenatal diagnosis laboratory, published in PMC (National Institutes of Health), put the numbers in stark relief:
| Condition | PPV (Lab Study) | PPV Range (Population Studies) | Practical Interpretation |
|---|---|---|---|
| Trisomy 21 (Down syndrome) | 86.1% | 65–84% | Most positive results are true positives; still confirm |
| Trisomy 18 (Edwards syndrome) | 57.8% | 35–62% | Roughly half of positive results may be false positives |
| Trisomy 13 (Patau syndrome) | 25.0% | 18–33% | Majority of positive results are false positives |
| Monosomy X (Turner syndrome) | 20–29% | 20–29% | Most positive results are false positives |
| Klinefelter syndrome (47,XXY) | 68–70% | 68–70% | Most positive results are true; confirm before acting |
| 47,XYY | 57–63% | 57–63% | Roughly half may be false positives |
| Microdeletions (e.g., 22q11.2) | Varies widely | Lower than trisomies | ACOG notes clinical validation is limited; confirm |
Large Chinese population cohorts — studying 17,428 pregnancies in one analysis — similarly found trisomy 21 PPVs of 65–84%, trisomy 18 of 35–62%, and trisomy 13 of 18–33%, consistent with the lab-study findings above.
Why Does Maternal Age Matter for Interpreting a Positive NIPT?
PPV is not static — it rises and falls with the underlying prevalence of the condition in the person being tested. And prevalence of chromosomal conditions is strongly linked to maternal age.
This is why age matters so much when interpreting a positive NIPT. Because trisomy 21, trisomy 18, and trisomy 13 all become more common as women age, the probability that a positive result is real increases with maternal age. In the same PPV analysis from PMC (NIH), women of advanced maternal age (35 or older) had a combined PPV of 64.9% for the common trisomies, compared to 45.8% in younger women — a gap large enough to meaningfully shift the conversation. In pregnancies with multiple compounding risk factors, combined trisomy PPVs approached 97%.
The clinical takeaway: a positive NIPT at 42 carries very different statistical weight than the same result at 24. Both warrant confirmatory testing, but neither should be treated as equivalent to a diagnosis at any age.
Maternal body mass index (BMI) introduces another layer of complexity. A nine-year analysis of 38,160 cases published in Human Reproduction found that higher BMI is associated with lower fetal fraction — the proportion of placental DNA circulating in the maternal bloodstream. Lower fetal fraction correlates with elevated false-positive rates, particularly for monosomy X. This finding, while not a reason to delay testing, is worth discussing with your provider if elevated BMI is relevant to your situation.
What Are the Biological Sources of NIPT False Positives?
NIPT measures cell-free DNA (cfDNA) shed by the placenta into the maternal bloodstream — it does not sample fetal DNA directly. That distinction is the root cause of most false positives, and it matters for how you interpret a high-risk result.
The main biological sources of false positives include:
- Confined placental mosaicism (CPM). A chromosomally abnormal cell line exists in the placenta but not in the fetus. Because NIPT reads placental DNA, it detects the abnormality — but the fetus is unaffected. CPM is the leading explanation for discordant NIPT results, particularly for sex chromosome findings.
- Maternal chromosomal variants. The mother herself may carry a chromosomal variant that contributes to the cfDNA signal. In rare cases, maternal somatic mosaicism — abnormal cells circulating in the mother's own bloodstream — can generate a false-positive flag.
- Vanishing twin. If a twin was reabsorbed early in the pregnancy, its DNA may still be circulating in the maternal bloodstream at the time of NIPT, producing a chromosomal signal that does not reflect the surviving fetus.
- Undiagnosed maternal malignancy. This is rare, but cancer-related cfDNA can occasionally produce signals that mimic chromosomal abnormalities. When a positive NIPT cannot be confirmed by invasive testing and no fetal cause is identified, providers may consider maternal evaluation.
Each of these sources underscores the same clinical principle: a positive NIPT is the beginning of an investigation, not the end of one.
What Should Happen After a Positive NIPT Result?
The guidance from ACMG, ACOG, and SMFM is consistent and unambiguous on this point: no irreversible clinical decision should be made based on a positive NIPT result without confirmatory diagnostic testing.
The two confirmatory options are:
- Chorionic villus sampling (CVS) — performed from 10 to 13 weeks, retrieves placental tissue genetically identical to the fetus, and can return results in the first trimester.
- Amniocentesis — performed from 15 weeks, withdraws amniotic fluid containing fetal cells, and is the more commonly performed confirmatory test in the second trimester.
ACOG now recommends that the material retrieved by either procedure be analyzed by chromosomal microarray rather than a standard karyotype, because microarray detects submicroscopic deletions and duplications that karyotyping misses. The ACOG January 2026 Practice Advisory and SMFM Consult Series No. 74 (November 2025) both reinforce that patients have made irrevocable decisions based on unconfirmed NIPT findings — a documented patient safety issue that the medical community is actively working to prevent.
ACMG also provides open-access ACT (Action) sheets for each positive NIPT scenario, giving clinicians step-by-step guidance on patient counseling and next steps after a positive result. These are available through the ACMG website and are a useful tool to ask your provider about.
If your NIPT flagged a microdeletion syndrome — such as 22q11.2 deletion syndrome — it is especially important to request confirmatory testing before drawing conclusions. ACOG has specifically noted that cfDNA screening for microdeletions has not been clinically validated to the same standard as common trisomy screening. Because each microdeletion syndrome is individually rare, PPVs for microdeletion flags are considerably lower than for trisomy 21. A maternal-fetal medicine specialist and a board-certified genetic counselor are your best resources for putting a microdeletion result in context.
How to Have a Productive Conversation With Your Provider
Receiving a positive NIPT result is frightening, and it can feel like you need to make decisions immediately. The data above should offer some measured reassurance: a positive result does not mean your baby has the condition. It means the probability has increased enough to warrant more information.
When you speak with your OB-GYN, midwife, or maternal-fetal medicine specialist, it helps to ask specifically:
- What is the estimated PPV for this specific result given my age and other risk factors?
- What confirmatory testing do you recommend, and what are the risks of that procedure?
- Can we arrange a consultation with a genetic counselor before I decide on next steps?
- What would a negative confirmatory test tell us, and how definitive is it?
Board-certified genetic counselors are the specialists trained to translate screening statistics into actionable, individualized guidance. Most major NIPT laboratories — including Natera, Myriad, and Labcorp — offer access to genetic counseling at no additional cost. If your provider's office cannot arrange a referral quickly, contact the laboratory directly or reach out to the National Society of Genetic Counselors (NSGC) to find a counselor in your area.
A positive NIPT opens a door to more information. It does not close one. Understanding PPV is the clearest way to hold that door open with both steadiness and clear eyes.
Frequently asked
What does a positive NIPT result actually mean?
A positive NIPT result means the test detected a pattern in the placental cell-free DNA that is consistent with a chromosomal condition — but it does not confirm that condition in your baby. NIPT is a screening test, not a diagnostic one. The result is expressed as a probability, and how meaningful that probability is depends heavily on which condition was flagged and your individual risk factors. ACOG's January 2026 Practice Advisory and the SMFM Consult Series No. 74 both emphasize that no clinical action — including decisions about the pregnancy — should be based on a positive NIPT result alone without confirmatory diagnostic testing via amniocentesis or CVS.
What is positive predictive value (PPV) and why does it vary so much?
Positive predictive value (PPV) is the probability that a positive test result reflects a true finding — in this case, that the fetus actually has the flagged chromosomal condition. PPV is not a fixed property of NIPT; it shifts based on how common the condition is in the population being screened. Rarer conditions produce fewer true positives in any screened group, so even a very specific test generates a higher proportion of false positives. A systematic analysis of 468 NIPT-positive cases published in PMC (NIH) found PPVs of 86.1% for trisomy 21, 57.8% for trisomy 18, and only 25.0% for trisomy 13 — meaning that roughly three out of every four positive trisomy 13 results in a general obstetric population are false positives.
Why are sex chromosome NIPT results often false positives?
Sex chromosome aneuploidies (SCAs) — conditions involving an abnormal number of X or Y chromosomes — have particularly variable and often low PPVs. For monosomy X (Turner syndrome), published estimates range from only 20% to 29%, meaning the majority of positive results are false positives. The reason is two-fold: monosomy X is rare in live births (most monosomy X conceptions miscarry early), and a biological phenomenon called confined placental mosaicism (CPM) can create an NIPT signal for monosomy X even when the fetus has a completely normal karyotype. By contrast, Klinefelter syndrome (47,XXY) has a PPV of roughly 68–70%, reflecting its higher prevalence in live births. These numbers come from a large PPV study published in PMC (NIH) and reinforce why confirmatory testing is essential for any sex chromosome result.
Does maternal age affect how reliable a positive NIPT result is?
Yes — significantly. Because chromosomal conditions like trisomy 21 become more common with advancing maternal age, the prior probability that a positive result is real rises with age. In one large PPV study, women 35 and older had a combined PPV of 64.9% for common trisomies, compared to 45.8% in younger women — a clinically meaningful gap. In high-risk pregnancies with multiple compounding factors, combined PPVs for T21, T18, and T13 approached 97%. This is why a positive NIPT at 42 carries very different clinical weight than the same result at 24 with no other risk factors. Your provider will factor in your age, personal and family history, and any ultrasound findings when interpreting the result. See the full PPV analysis at PMC (NIH) for the age-stratified data.
What are the biological reasons a positive NIPT can be wrong?
False-positive NIPT results arise from several distinct biological sources. The most common is confined placental mosaicism (CPM) — a chromosomally abnormal cell line present only in the placenta, not the fetus. Because NIPT reads placental DNA, not fetal DNA directly, it can detect CPM as though the fetus were affected. Additional sources include maternal chromosomal variants, maternal somatic mosaicism (abnormal cells circulating in the mother's bloodstream), a vanishing twin that was reabsorbed early in the pregnancy but still contributes DNA, and — rarely — an undiagnosed maternal malignancy, where cancer-related cfDNA can produce signals that mimic a chromosomal abnormality. According to Labcorp Women's Health, discordant results from any of these causes highlight why diagnostic confirmation is essential before clinical decisions are made.
What confirmatory testing should follow a positive NIPT result?
Both ACMG and ACOG are unambiguous: a positive NIPT result should be followed by diagnostic invasive testing — either chorionic villus sampling (CVS, performed from 10 weeks) or amniocentesis (from 15 weeks) — before any irreversible clinical decision is made. The retrieved fetal material is then analyzed by chromosomal microarray, which can detect submicroscopic deletions and duplications that a standard karyotype misses. The ObG Project (January 2026) reports that patients have made irrevocable pregnancy decisions based on positive NIPT results without follow-up confirmation — a documented patient safety problem that both ACOG's Practice Advisory and SMFM Consult Series No. 74 explicitly address. Genetic counseling before and after confirmatory testing helps families interpret results with full context.
Do microdeletion NIPT panels carry the same accuracy as trisomy screening?
No — and this is an important distinction. ACOG has specifically noted that cfDNA screening for microdeletions has not been clinically validated to the same standard as common trisomy screening. Because each individual microdeletion syndrome is very rare, the PPV for a positive microdeletion result is considerably lower than for trisomy 21 or 18 — even when the test's sensitivity and specificity are technically high. This means the proportion of false positives is higher for microdeletion flags. ACOG Practice Bulletin No. 226 (reaffirmed 2024) cautions that this lower PPV further reinforces the need for confirmatory invasive diagnostic testing before any clinical action is taken. If your NIPT flags a microdeletion such as 22q11.2, seek a referral to a maternal-fetal medicine specialist and a board-certified genetic counselor before drawing conclusions. See ACOG Practice Bulletin No. 226 for the full guidance.